Free Trial
NASDAQ:ONVO

Organovo 5/31/2024 Earnings Report

Organovo EPS Results

Actual EPS
-$3.48
Consensus EPS
-$5.04
Beat/Miss
Beat by +$1.56
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$50.00 thousand
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Organovo Earnings Headlines

Two new option listings and one option delisting on April 24th
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat